David Kolesky

David Kolesky has a diverse work experience in the field of biotechnology and bioengineering. David started their career as a PHD student at the Lewis Research Group at the University of Illinois at Urbana-Champaign, where they developed conductive inks and co-invented high-throughput microfluidic printheads for 3D printing. David then pursued their Ph.D. in Materials Science and Engineering at Harvard University, where they focused on 3D bioprinting of vascularized tissue constructs. After completing their Ph.D., David worked as a Postdoctoral Fellow at the Harvard John A. Paulson School of Engineering and Applied Sciences, where they developed materials and 3D printing methods for building vascularized tissues.

In 2016, David joined Senda Biosciences as a Co-Founder, where they contributed to the development of new categories of medicines based on interspecies molecular connections in the human body. David also co-founded Montai Health in 2020 and served as the Co-Founder and Chief Innovation Officer, leading the development of digital technologies to create Anthromolecule medicines for chronic disease treatment.

David has also worked at Invaio Sciences as the Head of iLabs, at the Wyss Institute for Biologically Inspired Engineering as a Technology Development Fellow, and at Flagship Pioneering in various roles including Associate, Senior Associate, Fellow, and Principal. Currently, they are working as a Principal at MPM BioImpact.

Apart from their professional experience, David has also participated in the Harvard Mini-MBA program in 2014, which aimed to expose non-business students to business school concepts.

David Kolesky received their Bachelor of Science degree in Materials Science and Engineering from the University of Florida between 2006 and 2010. David then pursued a Doctor of Philosophy (Ph.D.) in Materials Science and Engineering at Harvard University from 2012 to 2016, under the supervision of Jennifer Lewis in the Lewis Lab.